Potential of Personalized Dendritic Cell-Based Immunohybridoma Vaccines to Treat Prostate Cancer

Long-term first-in-man Phase I/II study of an adjuvant dendritic cell vaccine in patients with high-risk prostate cancer after radical prostatectomy

Cancer Vaccines for Genitourinary Tumors: Recent Progresses and Future Possibilities

Moving on From Sipuleucel-T: New Dendritic Cell Vaccine Strategies for Prostate Cancer

High Health-Related Quality of Life During Dendritic Cell Vaccination Therapy in Patients With Castration-Resistant Prostate Cancer

Consensus guidelines for the definition, detection and interpretation of immunogenic cell death

Targeting STAT3 enhances NDV-induced immunogenic cell death in prostate cancer cells

Substantial tumor regression in prostate cancer patient with extensive skeletal metastases upon Immunotherapy (APCEDEN): A case report

Blood-derived dendritic cell vaccinations induce immune responses that correlate with clinical outcome in patients with chemo-naive castration-resistant prostate cancer

Substantial remission of prostate adenocarcinoma with dendritic cell therapy APCEDEN in combination with chemotherapy